Britain and America have reached a landmark trade agreement that will ensure zero levies on UK medicine products entering the American market.
Key Provisions of the Deal
Under the terms of the agreement, the UK has committed to boost funding on drugs through the National Health Service (NHS). This commitment ensures that tariffs on these key exports will stay at zero for a period of 36 months.
This agreement comes after recent threats to significantly raise duties on branded drug products, with potential rates floated as high as one hundred percent.
"This deal between the United Kingdom reinforces the global environment for new treatments and establishes much-needed balance to U.S.–U.K. medicine commerce," a statement said.
Commercial Significance
Drugs represent one of the the United Kingdom's most significant exports to the United States, which is clearly the biggest destination for major British pharmaceutical firms.
Export figures show that in the year to the end of last September, the UK exported pharmaceutical products valued at £11.1bn to the US. This value accounted for a significant portion of total UK exports in that period.
"This guarantee safeguards employment, increases investment and paves the way for the UK to establish itself as a international leader for medical research," the Business and Trade Secretary stated.
Detailed British Pledges
The agreement involves several specific pledges from the British government:
- Higher Cost Ceiling: The UK will lift the price threshold at which it considers new treatments to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a aim to raise overall health service expenditure on medicines from 0.3 percent of GDP to 0.6 percent over the coming ten years.
- Payback Limit: The percentage drug companies must return to the NHS to prevent overspending will be capped at 15%. Last year, rebates were more than twenty percent.
Industry Background
This agreement comes amid a ongoing dispute between the sector and the British authorities over spending levels and regulatory access.
This friction were exacerbated by arguments that US customers were charged several times more for the same drugs than people in the Britain and the EU.
Over the last 18 months, several significant manufacturing plans in the UK have been halted or scrapped, while major funding commitments have been directed toward US facilities.
One official acknowledged that the NHS must increase expenditure on treatments, noting that its spending on drugs had declined as a percentage of its overall budget over the last ten years.
